News
Roche's NTRK tumour-agnostic therapy Rozlytrek approved in E...
Roche’s tumour-agnostic therapy Rozlytrek has been approved in the European Union for people with tumours with the NTRK mutation, meaning Bayer’s class rival faces competition in Europe for
